Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group-Reference-Cited by-同舟云学术

Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group

Published:2017-04 Issue:4 Volume:18 Page:454-463
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Borchmann Peter,Haverkamp Heinz,Lohri Andreas,Mey Ulrich,Kreissl Stefanie,Greil Richard,Markova Jana,Feuring-Buske Michaela,Meissner Julia,Dührsen Ulrich,Ostermann Helmut,Keller Ulrich,Maschmeyer Georg,Kuhnert Georg,Dietlein Markus,Kobe Carsten,Eich Hans,Baues Christian,Stein Harald,Fuchs Michael,Diehl Volker,Engert Andreas

Publisher

Elsevier BV

Subject

Oncology

Reference24 articles.

1. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis;Skoetz;Lancet Oncol,2013

2. Report of the Committee on Hodgkin's Disease Staging Classification;Carbone;Cancer Res,1971

3. Report of the Committee on Hodgkin's Disease Staging Procedures;Rosenberg;Cancer Res,1971

4. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease;Weihrauch;Ann Hematol,2002

5. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease;Gallamini;Haematologica,2006

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pulmonary diseases in patients with classical Hodgkin lymphoma relative to a matched background population: A Danish national cohort study;British Journal of Haematology;2024-04-29

2. Immune checkpoint inhibitors in advanced and relapsed/refractory Hodgkin lymphoma: current applications and future prospects;Frontiers in Oncology;2024-04-18

3. Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin’s lymphoma: results from the randomized international GHSG HD18 trial;Annals of Oncology;2023-12

4. Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma;International Journal of Molecular Sciences;2023-08-24

5. Quantitative PET-based biomarkers in lymphoma: getting ready for primetime;Nature Reviews Clinical Oncology;2023-07-17